New daily pill for weight loss enters human testing in china

NCT ID NCT07499050

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 6 times

Summary

This early-stage study tests a new daily pill, RO7795081, in 30 healthy Chinese adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body handles it. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RO7795081 (also known as CT-996, RG6652)
What this could lead to: If successful, this could lead to a new daily pill for weight management in people with obesity or overweight.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so it is primarily checking safety. The drug may not lead to significant weight loss or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Nanjing Gulou Hospital

Nanjing, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, 200003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.